course of primary sclerosing cholangitis (PSC) is highly variable and unpredictable. This study describes the natural history and outcome of PSC. These data were used to construct a prognostic model for patients with PSC. Methods-A total of 305 Swedish patients with PSC were studied. The median follow up time was 63 months and all patients could be traced for follow up. Some 79 patients died or had a liver transplant. The prognostic significance of clinical, biochemical, and histological findings at the time of diagnosis were evaluated using multivariate analysis. Results-The estimated median survival from time of diagnosis to death or liver transplantation was 12 years. Cholangiocarcinoma was found in 24 (8%) of the patients and 134 (44%) ofthe patients were asymptomatic at the time of diagnosis. The estimated survival rate was significantly higher in the asymptomatic group (p<0.001). However, 29 (22%) of the asymptomatic patients became symptomatic during the study period. It was found that age, serum bilirubin concentration, and histological stage at the time of diagnosis were independent predictors of a bad prognosis. These variables were used to construct a prognostic model. Conclusions-This prognostic model developed from a large homogeneous population of PSC patients should be of value for the timing oftransplantation and patient counselling in PSC.
Primary sclerosing cholangitis (PSC) is a chronic biliary destructive disease of unknown aetiology. The natural history is highly variable, some patients being asymptomatic for years, others rapidly progressing to premature death resulting from liver failure or cholangiocarcinoma.' 2 There is no effective treatment. With optimal timing for liver transplantation, however, excellent results have been achieved. [3] [4] [5] [6] It is therefore of importance to develop prognostic models that can be used to classify patients for therapeutic trials, for timing of liver transplantation, as well as in the counselling of patients. The results of studies from large referral centres are conflicting because of differences in sample size, referral patterns, definition of start and end point of the disease but may also be because of ethnic differences.7-'0 PSC is a heterogeneous disease and therefore it is important to describe the natural history and factors of prognostic importance in a homogeneous population.
The aim of this retrospective study was threefold: (a) to describe the natural history and outcome for 305 PSC patients of Swedish descent; (b) to evaluate the prognostic significance of clinical, biochemical, and histological findings at the time of diagnosis using multivariate analysis; and (c) to construct a prognostic model.
Methods

Patients
Three hundred and five patients of Swedish descent with PSC were included in the study. The patients were treated by doctors who are members of the Swedish Internal Medicine Liver Club (SILK) at nine hospitals throughout Sweden. The hospitals all serve both as primary and referral hospitals. Liver transplantation in Sweden is only performed at Huddinge and Sahlgrenska hospitals, both centres participating in the study. All patients that have been personally treated by the respective investigators were included in the study. The data were collected and verified using a questionnaire agreed upon in all centres by the investigators. 
Survival analysis
The estimated median survival time for the whole PSC group was 144 months. KaplanMeier survival curves showed a significantly better median survival for the asymptomatic patients than for those who were symptomatic at the time of diagnosis (112 months) (p<0.001) (Fig 1) .
Univariate and multivariate analysis The prognostic value of 19 variables present at the time of diagnosis were studied using univariate analysis (Table III) . Variables found to be of prognostic significance by univariate analysis were entered into a multivariate analysis. Symptoms were also tested in combination with each other. Using backward elimination as well as forward selection, four variables available at diagnosis of PSC were found to be of independent prognostic value: In Fig 2, a graph of estimated median survival is plotted against the prognostic index.
Discussion
This study describes the natural history of 305 PSC patients from Sweden, a country with approximately eight million inhabitants. In comparison 174 PSC patients from the United States and 126 from England, countries with considerably greater numbers of people have been presented.8 9 The prevalence of PSC in Swedish patients with UC has previously been described. ' Our material differs from that of the American and English studies in its high percentage of patients from the primary catchment area, probably giving a more representative reflection of the natural history of PSC.
The general characteristics of the patients in this study resemble those found in Norway, England, and the United States with a male predominance, a mean onset of disease around 40 years of age with a very large span (5-80 years) with respect to the age at diagnosis, and a close association with IBD.8 9 17 It can be argued that the inclusion of unspecified colitis (nine patients, 2%) into the IBD group is unjustified, but during the observation time some of the patients with unspecified colitis were reclassified as suffering from UC or CD. Thus, the prevalence of IBD is 8 1 % in this study whereas results of studies from the United States show (71%),8 England (71%),9 and Norway (100%).17 The Norwegian study is the only one in which all patients underwent colonoscopy and patients with unspecified colitis were included.
Twenty seven per cent of the patients in this study had intrahepatic PSC only. This is in agreement with a study from Yale,7 but in contrast with studies from both the Mayo Clinic8 and King's College Hospital9 showing a considerably lower percentage of patients with intrahepatic PSC only. Although real differences may exist between the various PSC populations, there may also be differences in anatomical definition of the extra and intrahepatic ductal system. The important differences between the PSC populations in the various studies seem, however, not to be found in the general characteristics of the patients but rather in the severity of the disease. In four studies describing the natural history of PSC the number of asymptomatic patients ranged from 1 5-25%,7-10 whereas a figure of 44% was noted in our study. Differences concerning definition of symptoms do exist between the previous studies. Fatigue was defined as a symptom in some studies7 9 but not in this one because of problems in defining this subjective symptom retrospectively. In the study by Farrant et al,9 fatigue was the most common symptom, reported by 65% of the patients.
This study comprises the largest number of asymptomatic PSC patients described; this may in part be explained by the high rate of patients with PSC restricted to the intrahepatic biliary tree, as 60% of these patients were asymptomatic. Significant differences between asymptomatic and symptomatic patients were found in survival, biochemical, and histological parameters, but also with respect to age at presentation and sex. Survival rate for the asymptomatic groups was 700/0 at 16 years after diagnosis (Fig 1) . This benign course for the asymptomatic group is in agreement with the study by Heltzberg.7 However, 22% of all asymptomatic patients developed symptoms during a median observation time of 69 months, and approximately 13% of the asymptomatic patients died or had liver transplants. This emphasises the progressive nature of PSC even in the asymptomatic group.
Despite the pronounced differences in survival between symptomatic and asymptomatic patients, the only symptom that was found to be of independent prognostic significance using multivariate analysis was variceal haemorrhage, which occurred in only 4%/o of all patients.
Differences in both definition of start and end point of the disease may influence actuarial survival time in different studies. In the study from King's College Hospital, reporting an estimated median survival time of 12 The reliability of a description of the natural history of a disease depends upon the size of a patient cohort in relation to the size of the background population. The importance of sample size may well be illustrated in the multicentre study presented by Dickson et al.'0 The prognostic significance of different variables was calculated for 426 PSC patients. For most of these patients, prognostic factors had been calculated in smaller separate studies. The factors found to be of prognostic importance in the large multicentre study differed from those identified in the smaller studies. The multicentre study showed that serum bilirubin concentration, histological stage at liver biopsy, age and, the presence of splenomegaly were independent predictors of high risk of dying. In our study with a large number of patients, bilirubin concentration, histological stage, and age were all factors found to be of prognostic significance.
The presence of splenomegaly was not evaluated in this study. The most accurate way to determine enlargement of the spleen is with isotopic scan, computed tomography or ultrasound. Although, one of these investigations had usually been done in our patients, the investigation had usually not been done at the same time as the time of diagnosis or the size of the spleen had not been described.
No investigated factors in this study could identify those PSC patients who would later develop cholangiocarcinoma. The detection rate of cholangiocarcinoma in 8% of the patients is comparable with that of other studies. It is probably an underestimation, however, as 3 1O% of all patients who died did not have a necropsy. Furthermore, cholangiocarcinoma is often difficult to diagnose in living patients with PSC.8 9 1820 Perhaps the introduction of time dependent variables into a dynamic prognostic model could be of value in the identification of PSC patients at risk for malignant transformation of the bile ducts. 2' We conclude that although genetic differences exist concerning HLA class II antigen association between Swedish, American, and English patients,22-26 the natural history and factors of prognostic importance seem more to be related to selection bias and sample size than to real differences between PSC patients from different countries.
